Yulzety (rivaroxaban)

Where it stands

Yulzety (rivaroxaban) is approved in the US. The records show an FDA approval on 2026-10-16 for Rosemont Pharms under NDA221033. The milestone is described as a new dosage form, specifically a suspension.

The records do not give a therapeutic area or an indication. They do not say which patient populations or uses the label covers. Any statement about clinical use would go beyond the data provided, so this analysis is limited to the regulatory event itself.

No CHMP opinion date is recorded. That is expected, because CHMP is the EU scientific committee and this is a US FDA action.

Regulatory pathway and designations

The only designation recorded is 'New dosage form'. In FDA terms, this indicates the approval concerns a new presentation of an already known active substance, here a suspension of rivaroxaban, rather than a new molecular entity. The NDA number (NDA221033) shows it was handled as a New Drug Application.

The records do not say which NDA route was used, such as a full application or one relying partly on existing data. They do not list the supporting studies, review designations (priority review, fast track and so on), exclusivity or the review timeline. None of these can be inferred from the records.

Rivaroxaban is already authorised in the EU under several names: Xarelto, Rivaroxaban Accord, Rivaroxaban Viatris (previously Rivaroxaban Mylan) and Svariya (previously Rivaroxaban Koanaa). This shows the substance has established regulatory precedent in another major region. The records do not link those EU products to Yulzety, and they do not say whether any EU product is a suspension.

Safety and pharmacovigilance

The records contain no safety data for Yulzety. They include no label text, boxed warnings, contraindications, risk management commitments (such as a REMS) or post-marketing requirements.

As a general point, a new dosage form of a known substance is normally assessed on its own for matters such as dosing accuracy, administration and formulation-specific risks. The records do not show whether any such issues were raised or addressed for Yulzety. Readers should consult the FDA-approved prescribing information for the safety profile and any dosing differences between formulations.

What to watch

The first step is to retrieve the approval letter and prescribing information for NDA221033. These would confirm the indication, the populations covered, dosing instructions for the suspension and any labelled safety measures. They would also show whether the approval carries post-marketing commitments.

Further points are not covered by the records. These include US launch timing, any equivalent filings in the EU or elsewhere, and how the suspension relates to the existing EU rivaroxaban products. Monitor FDA and company communications for these.